FILTER

FILTERED INTERVIEW RESULTS

Alan Petro

CEO, NEW VISION PHARMACEUTICALS
New Vision Pharmaceuticals explains how it is developing Blow-Fill-Seal technology and other services.

Thomas E. Bowens

FOUNDER AND PRESIDENT, IG GLOBAL GROUP & PRESIDENT AND CEO, TINTIC CONSOLIDATED METALS
Tintic Consolidated Metals explains to GBR how it is exploring the its’ vast gold/copper project in the Tintic district in Utah.

Manni Kantipudi & Ramesh Subramanian

CEO & CCO, ARAGEN LIFE SCIENCES
Aragen Life Sciences continues its rapid expansion and celebrates its best year ever.

Dr. Siva Samy

CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
ValGenesis explains how it streamlines the validation process to allow real-time access to validation documents and data enabling various stakeholders to achieve compliance efficiently.

Michael Kauffman

CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.

Eric Ostertag M.D., Ph.D.

CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.

Amit Munshi

PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.

Dr. Andrea Pfeifer

CO-FOUNDER & CEO, AC IMMUNE
AC Immune describes its research into neurodegenerative diseases.

Mark Egerton

CEO, QUOTIENT SCIENCES
Quotient Sciences is a drug development and manufacturing accelerator that supports pharmaceutical and biotech companies with services spanning the entire development pathway from candidate selection to commercial launch.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Latin America Petrochemicals and Chemicals 2024 - Digital Interactive

The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.

PARTNER EVENTS